Q3 EPS Forecast for Vera Therapeutics Reduced by Analyst

Key Points

• HC Wainwright has downgraded earnings estimates for Vera Therapeutics, predicting a loss of ($1.02) per share for Q3 2025, down from a prior forecast of ($0.87).
• Other analysts have shown mixed sentiments, with some reducing target prices while maintaining various ratings; the overall average rating for VERA is currently a Moderate Buy with an average target price of $63.00.
• Insider trading activity shows significant confidence, as Director Patrick G. Enright purchased over 209,000 shares at $20.87, increasing his stake in the company by 6.23%.

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Research analysts at HC Wainwright cut their Q3 2025 earnings per share (EPS) estimates for Vera Therapeutics in a report released on Wednesday, August 6th. HC Wainwright analyst A. He now expects that the company will post earnings of ($1.02) per share for the quarter, down from their prior estimate of ($0.87). HC Wainwright has a "Buy" rating and a $85.00 price objective on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics' Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($4.03) EPS, Q1 2026 earnings at ($0.94) EPS, Q2 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($0.95) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($3.10) EPS, FY2027 earnings at $0.65 EPS, FY2028 earnings at $3.36 EPS and FY2029 earnings at $5.89 EPS.

A number of other research firms have also issued reports on VERA. Wolfe Research reiterated a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Cantor Fitzgerald decreased their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. JPMorgan Chase & Co. cut their price target on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Guggenheim reaffirmed a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Finally, Scotiabank reissued an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $63.00.

Vera Therapeutics Trading Up 2.1%

Shares of Vera Therapeutics stock traded up $0.42 during trading hours on Friday, reaching $20.59. The stock had a trading volume of 807,447 shares, compared to its average volume of 1,287,098. The firm has a 50 day simple moving average of $22.74 and a two-hundred day simple moving average of $24.92. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -5.74 and a beta of 1.17. The company has a current ratio of 17.03, a quick ratio of 17.03 and a debt-to-equity ratio of 0.16. Vera Therapeutics has a 1 year low of $18.53 and a 1 year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same period in the prior year, the firm posted ($0.62) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of VERA. GF Fund Management CO. LTD. purchased a new position in shares of Vera Therapeutics during the fourth quarter valued at $56,000. Quarry LP grew its holdings in shares of Vera Therapeutics by 25.0% during the first quarter. Quarry LP now owns 2,500 shares of the company's stock valued at $60,000 after buying an additional 500 shares in the last quarter. AlphaQuest LLC grew its holdings in shares of Vera Therapeutics by 404.7% during the first quarter. AlphaQuest LLC now owns 4,007 shares of the company's stock valued at $96,000 after buying an additional 3,213 shares in the last quarter. Fifth Third Bancorp purchased a new position in shares of Vera Therapeutics during the second quarter valued at $102,000. Finally, Summit Investment Advisors Inc. grew its holdings in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after buying an additional 639 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company's stock.

Insider Activity

In related news, Director Patrick G. Enright bought 209,393 shares of the firm's stock in a transaction that occurred on Monday, June 23rd. The shares were acquired at an average cost of $20.87 per share, for a total transaction of $4,370,031.91. Following the acquisition, the director directly owned 3,569,522 shares of the company's stock, valued at $74,495,924.14. The trade was a 6.23% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 16.30% of the stock is owned by insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.